To ensure you don’t miss out on interesting IP law developments reported on our other IP blogs, we will, on a regular basis, provide you with an overview of the top 3 most-read posts from each of our…
On April 3, 2017, the latest decision was handed down in the patent revocation battle between medical device manufacturer Nouvag and Jean Malak, a plastic surgeon specialized in liposuction. This…
Pharmaceutical polymorph patents are regarded as effective means and important secondary pharmaceutical patents to extend the life cycle of pharmaceutical patent protection. However, the…
To the extent that the Patent Trial and Appeal Board did not provide an explanation for its obviousness rejection of 13 claims of a Securus patent on a system and method for reviewing monitored…
An EPO board of appeal expressed its opinion that EBA case law implied that no further use should be made of the three-part “essentiality test” of T 331/87, for deciding whether removal of a feature…
In this case, the Federal Court of Justice considered the value of a secondary indicium for a decision on inventive step. The FCJ confirmed that if an invention differs from the decades-old general…
A board of appeal of the European patent office held that a decision to reject an opposition with grounds based on an improperly corrected version of the patent as granted maintains the text used in…
In the past decade, a new character of the patent theatre has made inroads into the case law of some EU Member States, "imported" from the so-called "EPO case law". Its name is "plausibility".
The…
The UK Parliament closed down for business yesterday, preceding the general elections of 8 June 2017. It means parliamentary approval of legislation which is necessary for UK ratification of the…
The Unitary Patent system adds to territorial fragmentation of patent law in Europe, rather than consolidating it, by leaving aside non-participating EU Member States. Also, it is based on rules in…
